GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Net Current Asset Value

Biomerica (Biomerica) Net Current Asset Value : $0.38 (As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Biomerica's net current asset value per share for the quarter that ended in Feb. 2024 was $0.38.

The historical rank and industry rank for Biomerica's Net Current Asset Value or its related term are showing as below:

BMRA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.46   Med: 6.79   Max: 33.56
Current: 1.75

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Biomerica was 33.56. The lowest was 1.46. And the median was 6.79.

BMRA's Price-to-Net-Current-Asset-Value is ranked better than
82.51% of 589 companies
in the Medical Devices & Instruments industry
Industry Median: 4.96 vs BMRA: 1.75

Biomerica Net Current Asset Value Historical Data

The historical data trend for Biomerica's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Net Current Asset Value Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 1.00 0.54 0.50 0.60

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.60 0.54 0.46 0.38

Competitive Comparison of Biomerica's Net Current Asset Value

For the Medical Devices subindustry, Biomerica's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Biomerica's Price-to-Net-Current-Asset-Value falls into.



Biomerica Net Current Asset Value Calculation

Biomerica's Net Current Asset Value (NCAV) per share for the fiscal year that ended in May. 2023 is calculated as

Net Current Asset Value Per Share(A: May. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(12.797-2.73-0-0)/16.8216
=0.60

Biomerica's Net Current Asset Value (NCAV) per share for the quarter that ended in Feb. 2024 is calculated as

Net Current Asset Value Per Share(Q: Feb. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(8.846-2.534-0-0)/16.8216
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica  (NAS:BMRA) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Biomerica Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Biomerica's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663